Results 151 to 160 of about 4,101 (234)

Booster and Btki Interruption Improve Response to Sars-Cov-2 Vaccine in Patients with CLL

Blood, 2022
Bryer, Emily, Paul, Shira, Chen, Jonathan, Pleyer, Christopher, Wiestner, Adrian, Sun, Clare   +5 more
openaire   +1 more source

A single-center retrospective study suggests a potential benefit of BTK inhibitor-based therapy in patients with histologic transformation of Waldenström macroglobulinemia. [PDF]

Ann Med
Xia Y, Shen H, Miao Y, Zhao Y, Liu H, Wang S, Tian T, Xu J, Qu X, Li J, Fan L.   +10 more
europepmc   +1 more source

MCL-373 Unmet Need in Relapsed/Refractory (RR) Mantle Cell Lymphoma (MCL) Post-Bruton Tyrosine Kinase Inhibitor (BTKi): Systematic Literature Review and Meta-Analysis

, 2023
Martin Dreyling, Bijal Shah, James J. Wu, Taha Itani, Michael J. Zoratti, Steve Kanters, Sally W. Wade, Weimin Peng, Jean‐Gabriel Castaigne, Ioana Kloos, Michael Wang   +10 more
openalex   +1 more source

Acalabrutinib May Offer a New Therapeutic Approach for Consolidation and Maintenance of Primary CNS Lymphoma with Expression of MYD88 and CD79B Gene Variants: A Case Report and Literature Review of Primary CNS Lymphoma in the BTKi Era [PDF]

E. Allison, Ashlea Campbell, Anne-Marie Watson, Brendan Beaton   +3 more
openalex   +1 more source

Peripheral neuropathy and BTKis in Waldenström: a response?

Blood Advances
Chiara Briani, Bruno Ferrero, Alessandro Salvalaggio, Simone Ragaini, Enrico Amaducci, Irene Dogliotti, Andrea Visentin, Simone Ferrero   +7 more
openaire   +3 more sources

Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma. [PDF]

Blood Adv
Darnell EP, Gallagher KME, Kanska J, Scarfò I, Balderrama-Gutierrez G, Berger TR, Budka J, Bozym DJ, Huang T, Shen R, Leick MB, Maus MV.   +11 more
europepmc   +1 more source

P1005: EFFECT OF TL-895, A NOVEL BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ON ONCOGENIC JANUS KINASE 2-V617F (JAK2VF) SIGNALING

, 2023
Subbaiah Chary Nimmagadda, Paulina Marie Budde, Kaiyan Sun, Todd Covey, Cecile M. Krejsa, Wayne P. Rothbaum, Nikolas von Bubnoff, Cyrus Khandanpour   +7 more
openalex   +1 more source

When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia. [PDF]

Curr Hematol Malig Rep
Benrashid S, Woyach JA.
europepmc   +1 more source

Brexucabtagene autoleucel in‐vivo expansion and BTKi refractoriness have a negative influence on progression‐free survival in mantle cell lymphoma: Results from CART‐SIE study [PDF]

Federico Stella, Annalisa Chiappella, Martina Magni, Francesca Bonifazi, Chiara De Philippis, Maurizio Musso, Ilaria Cutini, Silva Ljevar, Anna Maria Barbui, Mirko Farina, Massimo Martino, Massimo Massaia, Giovanni Grillo, Piera Angelillo, Barbara Botto, Francesca Patriarca, Mauro Krampera, Luca Arcaini, Maria Chiara Tisi, Pier Luigi Zinzani, Federica Sorà, Stéfania Bramanti, Martina Pennisi, Cristiana Carniti, Paolo Corradini   +24 more
openalex   +1 more source

[Efficacy and safety analysis of BTK inhibitors combined with R-CHOP regimen in newly diagnosed double-expressor diffuse large B-cell lymphoma]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Lu JB, Cao L, Liu HL, Miao Y, Shen HR, Xia Y, Yin H, Cheng YX, Li JY, Fan L.   +9 more
europepmc   +1 more source